Christopher Dalziel
Christopher Dalziel
Divina Glah
Divina Glah
American Society of Clinical Oncology--44th Annual Meeting. Reports of clinical trial results--part 2 [0.03%]
美国临床肿瘤学会年会报告-临床试验结果(二)
Erhimuvi Ogbighele
Erhimuvi Ogbighele
Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies [0.03%]
一种用于潜在治疗多种恶性肿瘤的二氢叶酸还原酶抑制剂普拉替雷克注射液
Julian R Molina
Julian R Molina
Pralatrexate, a 10-deazaaminopterin derivative, is being developed by Allos Therapeutics Inc for the potential treatment of malignancies. The folate analog inhibits dihydrofolate reductase and was developed to overcome the limitations of th...
Drug development for children: how is pharma tackling an unmet need? [0.03%]
儿童药物开发：医药行业如何应对这一尚未满足的需求？
Daniel B Hawcutt,Rosalind L Smyth
Daniel B Hawcutt
The laws and regulatory processes that govern the pharmaceutical industry have previously had the unintended consequence of excluding children in the drug development process. Many of the medicines prescribed to children consist of either a...
Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility [0.03%]
用基于肠降糖激素的治疗替代手术治疗2型糖尿病：挑战与可行性分析
Filip K Knop,Jens J Holst,Tina Vilsbøll
Filip K Knop
Type 2 diabetes mellitus (T2DM) is a progressive disease characterized by insulin resistance, a steady decline in glucose-induced insulin secretion (most likely caused by a progressive decrease in functional beta-cell mass), and inappropria...